Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 02179 RECBIO-B > Detailed Quotes

02179 RECBIO-B

Watchlist
24.350
-0.150-0.61%
Closed  02/08 16:08 CCT
High
24.500
Open
24.350
Turnover
4.70M
Low
23.850
Pre Close
24.500
Volume
194.00K
Market Cap
11.76B
P/E(TTM)
Loss
52wk High
28.300
Shares
482.96M
P/E(Static)
Loss
52wk Low
17.720
Float Cap
2.28B
Bid/Ask %
-53.85%
Historical High
28.300
Shs Float
93.64M
Volume Ratio
1.03
Historical Low
17.720
Dividend TTM
--
Div Yield TTM
--
P/B
5.00
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.21%
Amplitude
2.65%
Avg Price
24.205
Lot Size
500
Float Cap
2.28B
Bid/Ask %
-53.85%
Historical High
28.300
Shs Float
93.64M
Volume Ratio
1.03
Historical Low
17.720
Dividend TTM
--
P/B
5.00
Dividend LFY
--
Turnover Ratio
0.21%
Amplitude
2.65%
Avg Price
24.205
Lot Size
500
Price Forecast

News

Comment

Company Overview More
Jiangsu Ruike Biotechnology Co., Ltd. (“Ricoh Biotech” or the “Company”) is an innovative vaccine company committed to developing and commercializing safer and more effective innovative vaccines to address public health needs that are far from being met. Ricoh Biotech has high-value vaccine packages and is driven by self-developed novel adjuvant technology and protein engineering technology. Through the company's strong R&D capabilities, a powerful innovative vaccine portfolio composed of 11 vaccine candidates has been established, and coverage has been strategically expanded to include 5 of the 10 most burdensome diseases in the “Global Burden of Disease” assessed by DALYs published by the World Health Organization in 2019, and the disease fields covered by 3 of the 5 best-selling vaccine products in the world in 2020. Currently, the company's core product, REC603, a recombinant HPV nine-valent vaccine, is in phase III clinical trials. The company has formulated a clear commercialization strategy in China and overseas with the aim of further penetrating diversified markets around the world. At the same time, the company has developed three advanced technology platforms for novel adjuvant development, protein engineering, and immune evaluation. These platforms enable companies to continuously discover and develop innovative vaccines and apply advanced technology to vaccine candidates. The company completed Series A financing in 2019, Series B financing in 2020, and completed Series B+ financing and Series C financing in 2021, respectively.
CEO: Yong Liu
Market: Hong Kong motherboard
Listing Date: 03/31/2022
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist